Medicines for weight loss and diabetes continue to be among the main drivers of the pharmaceutical industry. In a critical market, Novo Nordisk lost two patents in the last few daysso now it competes with generics that have lower prices.
Founded in Denmark, Novo Nordisk manufactures Ozempic and Wegovi, two drugs with great sales around the world. No, India is one of the biggest markets in this context, since more than 300 million people are overweight or obese and 100 million people suffer from diabetes. The demand is so great that several pharmaceutical companies are looking to explore it.
As Novo Nordisk patents in India about those medicines expired on FridayMarch 20th. Thus, at least five local pharmaceutical companies have already launched own generics, with price reductions of up to 80%according to the North American station CNBC.
Leave a Reply